ANAC, Anacor Pharmaceuticals, announce positive results, 03/22/2013

Sunday, 24 March 2013 - staff

ANAC, Anacor Pharmaceuticals, announce positive results, 03/22/2013

Anacor Pharmaceuticals Announces Positive Results From Phase 2 Dose-Ranging Study of AN2728 in Adolescents With Atopic Dermatitis

PALO ALTO, Calif.--(BUSINESS WIRE)--

Anacor Pharmaceuticals (ANAC) today announced positive results from a Phase 2 dose-ranging trial (AN2728-AD-204) of its topical boron-based phosphodiesterase-4 (PDE-4) inhibitor, AN2728. The study included 86 adolescents (ages 12 – 17) with mild-to-moderate atopic dermatitis, a chronic rash which predominantly affects children and is characterized by inflammation and itching. In this study, lesions treated with AN2728 ointment, 2.0% twice daily for 28 days achieved a 71% improvement from baseline in their Atopic Dermatitis Severity Index (ADSI) score, with 66% of lesions in this treatment group achieving total or partial clearance. AN2728 was generally safe and well-tolerated. Most adverse events were mild and largely unrelated to study drug.

“These results demonstrate a clear dose response across the four dosing regimens and identify the AN2728 ointment, 2.0% BID dosing regimen as optimal for a Phase 3 program, which we expect to initiate around the end of 2013,” said David Perry, Chief Executive Officer of Anacor Pharmaceuticals. “In all arms of the study, lesions treated with AN2728 ointment improved throughout the 28 day treatment period. The majority of the improvement occurred within the first week of treatment, which is important to both patients and physicians. AN2728 also continues to demonstrate an excellent safety profile - a key factor in treating this disease that primarily affects children.”

“There is a tremendous clinical need for safe and effective treatments for pediatric atopic dermatitis. It is very exciting to see these promising positive data for a novel molecule with excellent anti-inflammatory properties and that appears very safe to use,” said Lawrence F. Eichenfield, M.D., Chief of Pediatric and Adolescent Dermatology and Professor of Pediatrics and Medicine (Dermatology) at Rady Children's Hospital, University of California, San Diego. “AN2728 has the potential to be an outstanding addition to the treatment armamentarium for physicians and a great benefit to children with atopic dermatitis.”

Sources: Anacor Pharma, OxBridge Research, Daily Stock Deals

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

Get the Fresh, Nutrient Rich, Piping Hot Picks Everyday! Sign-up, its FREE!

George Soros $1 billion dollar Yen trade, Soros pocketed cool billion dollars on each trade,

Saturday, 16 February 2013 - Staff

If George can do, so can you! If Soros Can Make $1 Billion on Yen Trade, You can too?

It was Soros second $1 billion dollar trade. Soros pocketed cool billion dollars on each trade,once betting against a central bank, this time betting with the central bank.

Nobody should be surprised that a bunch of hedge-fund boys piggybacked onto Shinzo Abe’s campaign pledge to drive down the yen. What is surprising are the fantastic sums people like George Soros cleared in just a couple of months, and if the new Japanese prime minister gets his man in at the Bank of Japan, the easy yen trade may have legs.

Wagering against the yen has emerged as the hottest trade on Wall Street over the past three months. George Soros, who made a fortune shorting the British pound in the 1990s, has scored gains of almost $1 billion on the trade since November, according to people with knowledge of the firm’s positions. Others reaping big trading profits by riding the yen down include David Einhorn’s Greenlight Capital, Daniel Loeb’s Third Point LLC and Kyle Bass’s Hayman Capital Management LP, investors say.

When names like Soros, Einhorn, Loeb, and Bass, and a figure like $1 billion, get attached to a trade, you can imagine that mere mortals will start salivating. But can little guys maneuver like the likes of Soros? Is this trade a rent, or a buy? Also, not for nothing, but if the story’s on the front page of the Wall Street Journal, will that alone wreck the trade, as it’s now out there for anybody and everybody to see, and crowd into? Are Soros and the rest already selling?

Learn more: http://www.oxbridgeresearch.com/

http://online.wsj.com/home-page

http://www.dailystockdeals.com/

soros billion dollar win, soros billion dollar trade,soros yen trade,soros euro trade, soros betting against dollar,forex trading,soros Pound trade,USD/JPY pair win a jackpot